Skip to main content
. 2021 Aug 14;12(3):1288–1304. doi: 10.1016/j.apsb.2021.08.015

Figure 1.

Figure 1

Z-GP-DAVLBH inhibits the proliferation of osteosarcoma cells in vitro. (A) The protein levels of FAPα in SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were determined by Western blotting analysis. (B) SJSA-1, 143B, hFOB 1.19 cells, and HBVPs were treated with Z-GP-DAVLBH (10 μmol/L) in the presence or absence of TAL for 2 h. The hydrolysis efficiency of Z-GP-DAVLBH was analyzed by LC–MS. HBVPs serve as an FAPα-negative control cells. ND, no detection. (C) Osteosarcoma cells (SJSA-1 and 143B) were treated with various concentrations of Z-GP-DAVLBH for 24, 48, and 72 h. Cell viability was detected by an MTT assay. (D) MTT assay was conducted to determine the effect of Z-GP-DAVLBH on the viability of hFOB 1.19 cells. (E) Osteosarcoma cells (SJSA-1 and 143B) were treated with Z-GP-DAVLBH (50 nmol/L for SJSA-1 cells and 100 nmol/L for 143B cells) for 48 h in the presence or absence of TAL. Cell viability was detected by MTT assay. (F) Cell colony formation assay of SJSA-1 and 143B cells treated with the indicated concentrations of Z-GP-DAVLBH. Representative images of cell colonies are shown and clonogenicity was quantitated by normalization to the untreated group. Magnification: 100×. (G) The cell cycle distribution was detected by flow cytometry analysis. (H) Cell cycle-associated proteins were analyzed by Western blotting analysis. Data are presented as mean ± SEM, n = 3; ∗∗∗P<0.001 vs. the untreated (0 nmol/L, 0.1% DMSO) group; ###P < 0.001 vs. the Z-GP-DAVLBH-treated group.